Patent intelligence · US
US 10005724
Therapeutic compounds and methods of use thereof
Therapeutic compounds and methods of use thereof
Patent details — US 10005724
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 26, 2018
- Expiration
- Jun 21, 2038
- Applicant
- Xenon Pharmaceuticals Inc.
- Claims
- 11
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P11/00
Quick answer
US 10005724 (Therapeutic compounds and methods of use thereof) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Xenon Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P11/00, A61P13/10, A61P17/04
More from Xenon Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12319657
Solid state crystalline forms of a selective potassium channel modulator
granted -
US 12178811
Methods of treating depressive disorders
granted -
US 12171759
Methods and uses for treating anhedonia
granted -
US 11957675
Methods and uses for treating anhedonia
granted -
US 11325902
Benzenesulfonamide compounds and their use as therapeutic agents
granted -
US 11299490
Benzenesulfonamide compounds and their use as therapeutic agents
granted -
US 11203572
Substituted benzamides and methods of use thereof
granted -
US 11174268
Benzenesulfonamide compouds and their use as therapeutic agents
granted
Frequently asked questions
What is US patent 10005724?
US 10005724 (Therapeutic compounds and methods of use thereof) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10005724?
Xenon Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 106 pharmaceutical patents for this assignee.
When does US 10005724 expire?
Our index shows an expiration date of Jun 21, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.